Revelation Biosciences (REVB) Current Leases (2021 - 2026)

Revelation Biosciences (REVB) posted quarterly Current Leases of $23013.0 for Q4 2025, up 37.37% quarter-over-quarter from $16752.0 in Q4 2021.

Revelation Biosciences (REVB) Current Leases (2021 - 2026) Analysis & Trends

Revelation Biosciences (REVB) has reported Current Leases for 2 consecutive years, with $23013.0 the latest figure, recorded in Q4 2025.

In Q4 2025, Current Leases changed N/A year-over-year to $23013.0; the TTM figure through Dec 2025 stood at $23013.0 (changed N/A YoY), while the FY2025 annual figure was $23013.0, changed N/A from the prior year.
Current Leases grew to $23013.0 in Q4 2025 per REVB's latest filing, from $16752.0 in the prior quarter.
Across five years, Current Leases topped out at $23013.0 in Q4 2025 and bottomed at $16752.0 in Q4 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Current Leases (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn	720.00 Mn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn	-
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn	-
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn	21.95 Mn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn	45.93 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn	-
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn	6.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-	-
10	Revelation Biosciences	4.17 Mn	-7.33 Mn	-	189,370.00

Download Data